EmilyKathleenCurranMD

Oncology • Cincinnati, OH

Hematologic Oncology

Physician

Join to view full profile

Dr. Curran is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Curran's full profile

Already have an account?

Office
3130 Highland Ave
Cincinnati, OH 45219
Phone+1 513-584-4268

Fax+1 513-584-6955

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2012 - 2015
University of ChicagoResidency, Internal Medicine, 2008 - 2011
Stanford University School of MedicineClass of 2008

Certifications & Licensure

OH State Medical License 2019 - 2025
IL State Medical License 2008 - 2020
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

50 citations
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
Amy Wang, Howard Weiner, Margaret Green, Hua Chang, Noreen Fulton
Journal of Hematology & Oncology. 2018-01-05
122 citations
STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.
Emily Curran, Xiufen Chen, Leticia Corrales, Douglas E. Kline, Thomas W. Dubensky
Cell Reports. 2016-06-14
73 citations
Mechanisms of Immune Tolerance in Leukemia and Lymphoma
Emily Curran, James Godfrey, Justin Kline
Trends in Immunology. 2017-07-01

Abstracts/Posters

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin
Emily K Curran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
Emily K Curran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Ponatinib and Blinatumomab Combination Safe and Effective in Patients with Newly Diagnosed, Ph-Positive ALLFebruary 3rd, 2023